The delivery of recombinant adeno-associated virus (rAAV) gene therapy vectors to muscle can result in long-term expression of transgenes that encode nonself proteins (12) . CD8 ϩ T cells targeting these proteins are maintained at low frequencies in the spleens and draining lymph nodes of mice (8, 9) but continuously infiltrate transduced muscle, where they undergo programmed death (14) . Stable CD8 ϩ T-cell frequencies can be maintained only if those that infiltrate and die in the muscle are replaced. Little is known, however, about mechanisms of class I antigen presentation and CD8 ϩ T-cell priming after persistent transgene expression is established. Vector transduction and antigen synthesis by dendritic cells is thought to be required for CD8 ϩ T-cell priming (2, 6, 10, (15) (16) (17) . Because transduced dendritic cells have a limited life span and rAAV gene therapy vectors do not replicate or spread to new cells, this mechanism cannot satisfy an apparent requirement for ongoing antigen presentation to CD8 ϩ T cells. Here we demonstrate that vector-transduced dendritic cells were not involved in CD8 ϩ T-cell priming. Instead, CD8 ϩ T cells were primed by dendritic cells that acquired antigen from rAAVtransduced muscle cells, suggesting that strategies to restrict transgene expression to nonprofessional antigen-presenting cells will not prevent T-cell immunity.
Evidence that dendritic cells cross-present antigens encoded by recombinant DNA or viral vaccine vectors was first obtained by examining patterns of CD8 ϩ T-cell priming in mice transplanted with bone marrow that was partially mismatched at H-2 class I loci (1, (3) (4) (5) . We adapted this approach to determine if dendritic cells acquire antigen from rAAV-transduced muscle to continuously prime CD8 ϩ T cells. As shown in Fig.  1A , DNase-resistant particles (5 ϫ 10 10 ) of serotype 1 or 2 rAAV vectors that encode ␤-galactosidase (␤-Gal) (rAAV1 ␤-Gal and rAAV2 ␤-Gal , respectively) were delivered to the quadriceps muscles of CB6F1 mice. Three weeks later, the mice were irradiated (two doses of 6 Gy separated by a 4-hour interval) and reconstituted with parental (H-2 b or H-2 d ) bone marrow that was depleted of T lymphocytes to prevent graft-versushost disease (Fig. 1B) (Fig. 1C , left or middle panel, respectively). Costaining with both antibodies was observed after the transfer of CB6F1 bone marrow (Fig. 1C, right panel) . Very importantly, ␤-Gal expression persisted in muscle through lethal irradiation and bone marrow reconstitution. As an example, similar levels of ␤-Gal protein were detected in the muscles of CB6F1 mice 21 and 63 days after vector delivery (Fig.  1D ). The later time point was 42 days after reconstitution with H-2 b bone marrow, so there was no substantial loss of transduced myocytes due to lethal irradiation that might facilitate the cross-presentation of antigen.
The temporal separation of rAAV vector delivery to muscle and immune system reconstitution by bone marrow transfer ( Fig. 2A) . The opposite pattern of epitope recognition was observed in animals that received the H-2 b bone marrow ( Fig. 2A) . Mice that received autologous (H-2 bxd ) bone marrow responded to both epitopes, as expected (data not shown). It is unlikely that the absence of a response restricted by the mismatched parental class I molecule was due to the skewing of the T-cell repertoire, as the same pattern of responsiveness was observed in both recipient mouse strains after a reciprocal bone marrow transplantation. Moreover, Tcell repertoires appeared normal in chimeric mice used in studies of plasmid DNA vaccines (5).
These results indicate that CD8 ϩ T cells are primed after persistent antigen production is established with an rAAV vector, providing an explanation for how the response is maintained despite the programmed death of effector populations that infiltrate transduced muscle (14) . Our failure to detect responses against both ␤-Gal epitopes in mice reconstituted with H- ϩ T-cell response that failed to eliminate transduced myocytes. CD8 ϩ T cells were primed even when vector delivery to muscle preceded reconstitution of the immune system by 3 weeks. It is very unlikely that parental dendritic cells were transduced with vector particles introduced into muscle 3 weeks earlier. In support of this argument, capsid-specific antibodies present at high titers in serum after vector delivery declined substantially following irradiation and immune reconstitution, suggesting that capsid antigens were not available to regenerate the response (Fig. 2B, left panel) . Antibodies to ␤-Gal were maintained before and after immune reconstitution, reflecting the persistence of antigen expression in muscle (Fig. 2B, right panel) 2C) . Capsid-specific CD8 ϩ T-cell responses were readily generated when an H-2 d immune system was transferred to F1 mice before vector delivery (Fig. 2 D and E) . CD8 ϩ T-cell responses were detected against the H-2 d -but not the H-2 brestricted ␤-Gal (Fig. 2E, left panel) and capsid (Fig. 2E, right  panel) epitopes. The opposite pattern of capsid-specific CD8 stitution (data not shown). These results are consistent with a requirement for dendritic cells to generate a response to particle-associated capsid proteins (11, 13) . Intramuscular delivery of rAAV1 ␤-Gal and rAAV2 ␤-Gal induced CD8 ϩ T-cell responses, even though the latter vector is thought to transduce dendritic cells inefficiently (7, 13) . Indeed, direct transduction of dendritic cells by rAAV vectors was not required for T-cell priming once persistent antigen expression was established in this model. The pattern of CD8 ϩ T-cell priming in bone marrow-reconstituted F1 mice is best explained by dendritic cell cross-presentation of antigen acquired from rAAV1 ␤-Gal -and rAAV2 ␤-Gal -transduced myocytes. Our observations also indicate that the use of cell-typespecific promoters that permit transgene expression in myocytes, but not dendritic cells, is unlikely to prevent CD8 ϩ T-cell priming, as was previously proposed (2) . Finally, the model described here may be generally useful to identify the defects in antigen presentation that reinforce priming of an ineffective CD8
ϩ T-cell response and may be important for successful gene therapy.
